Introduction
============

Inside the luminal breast cancer (BC) group, the B subclass carries a worse prognosis and is less responsive to hormonal treatment. Identification of the luminal B group, by Sørlie and colleagues \[[@B1]\], has been less consistent than other subclasses; and gene signatures based in estrogen-related genes or proliferation are better to identify this BC subclass. Cheang and colleagues genetically evaluated 144 luminal ER-positive HER2-negative tumors by IHC; they found a ki67 cutoff value of 13.25% to differentiate B from A subclasses \[[@B2]\]. No differentiation for PR status was done. The luminal B subgroup is usually defined as ki67 \>13 if ER-positive, as well as HER2-positive or PR-negative. The target of this abstract is to evaluate behavior of different luminal B subsets.

Methods
=======

We reviewed early BC cases evaluated at Hospital 12 de Octubre between 1995 and 2007 and selected 710 initially operated luminal B BC. We divided this group into four subsets as shown in Table [1](#T1){ref-type="table"} and analyzed their clinical-pathologic features and outcomes. Additionally, we evaluated the prognostic behavior of lowering the ki67 cutoff in the ER^+^PR^+^HER2^-^group (820 patients).

                                                   HER2^-^                                 
  ----------------------------- ------------------ ------------------ -------------------- ------------------
  Cases                         189                126                10                   385
  Median age (*P*= 0.0021)      53.49              60.3               49.7                 57.7
  Ductal (*P*= 0.002)           173 (91.5%)        98(77.8%)          10 (100%)            314 (81.5%)
  HG III (*P*= 0.03)            41%                47%                40%                  34.1%
  Lobular                       5.3%               17.5%              0                    14%
  Median ER                     85%                83%                0                    90%
  Median PR                     60%                0                  45%                  80%
  Median ki67                   20%                17%                12.5%                20%
  Recurrences total (%)         52 (27.5%)         32 (25.4%)         2 (20%)              81 (21%)
  Locoregional                  9 (17.3%)          3 (9.4%)           0                    15 (18.5%)
  Bone                          6 (11.5%)          14 (43.8%)         0                    25 (30.9%)
  Visceral (*P*= 0.04)          34 (65.4%)         11 (34.4%)         0                    36 (44.4%)
  Median (95% CI) DFS (years)   8.1 (6.5 to 8.7)   6.4 (5.4 to 7.2)   9.2 (7.6 to 11.9)    5.6 (5.2 to 6.1)
  Median (95% CI) OS (years)    8.7 (8.1 to 9.0)   7.0 (5.8 to 7.9)   10.5 (7.8 to 13.6)   6.1 (5.6 to 6.6)

Results
=======

The median ki67 value for the ER^+^PR^-^group was 17%. A ki67 cutoff at 14% discerns two groups of different prognosis inside the luminal group (extracting HER2^+^and PR^-^); and comparison of ki67 cutoff between 14 and 11% found overlapped CI (median: 6.31 (5.99 to 6.62) vs. 6.49 (6.21 to 6.78)). Table [1](#T1){ref-type="table"} summarizes different characteristics and prognosis based on molecular features (statistical comparisons exclude the ER^-^PR^+^subgroup).

Conclusion
==========

Subsets inside the luminal B subtype according to expression of HER2, ER, PgR and ki67 have different features and behaviors. In the ER^+^PR^+^HER2^-^subgroup, ki67 cutoff should be re-evaluated in order to avoid misclassification and subsequent under-treatment of poorer prognosis tumors as luminal A hormono-sensitive phenotype.
